AbbVie's Skyrizi takes home a win in late-stage Crohn's study, adding some heft to its expansion plans

AbbVie hasn’t been shy about its blockbuster ambitions for psoriasis med Skyrizi since launch, arguing it could go a long way to stanching the bleeding from Humira’s patent cliff. Now, the drugmaker is adding even more armor to Skyrizi’s chances at Crohn’s disease, a key indication in the drug’s expansion plans.